SCHEMBL16653607

SCHEMBL16653607

O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=S

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5330188 1.00
SCHEMBL7459049 0.97
SCHEMBL1697434 0.94
SCHEMBL3857933 0.84 AKR1B1 (0.37)
SCHEMBL1547638 0.84 AKR1B1 (0.37)
SCHEMBL23072256 0.84 AKR1B1 (0.37)
SCHEMBL31611656 0.84 AKR1B1 (0.37)
SCHEMBL12396667 0.77 AKR1B1 (0.37)
SCHEMBL15329241 0.73 AKR1B1 (0.30)
SCHEMBL9147251 0.73 AKR1B1 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727586-A1 ANTI-CD5 ANTIBODIES AND THEIR USES Synthis Therapeutics, Inc. (US) 2026-04-22 EP disclosed
EP-4674440-A2 SITE-SPECIFIC ANTIBODY-DRUG GLYCOCONJUGATES AND METHODS University of Georgia Research Foundation, Inc. (US) 2026-01-07 EP disclosed
EP-3129402-B1 SITE-SPECIFIC ANTIBODY-DRUG GLYCOCONJUGATES AND METHODS UNIV GEORGIA (US) 2025-11-26 EP disclosed
US-20250222124-A1 PROTEIN CONJUGATES WITH MULTIPLE PAYLOADS AND METHODS FOR MAKING THE SAME GLYCO-THERAPY BIOTECHNOLOGY CO., LTD. (CN) 2025-07-10 US disclosed
US-12281174-B2 High-affinity anti-MERTK antibodies and uses thereof INSPIRNA, INC. (US) 2025-04-22 US disclosed
CN-119735688-A High-affinity anti-MERTK antibodies and uses thereof 茵思博纳公司 2025-04-01 CN disclosed
CN-119488607-A Antibody-ALK 5 inhibitor conjugate and application thereof 辛瑟斯治疗股份有限公司 2025-02-21 CN disclosed
WO-2024258967-A1 ANTI-CD5 ANTIBODIES AND THEIR USES SYNTHIS THERAPEUTICS, INC. (US) 2024-12-19 WO disclosed
US-12162942-B2 Anti-MERTK agonistic antibodies and uses thereof THE ROCKEFELLER UNIVERSITY (US) 2024-12-10 US disclosed
CN-112601522-B Antibody-ALK 5 inhibitor conjugate and application thereof 辛瑟斯治疗股份有限公司 2024-11-05 CN disclosed
US-20160250347-A1 MODIFIED GLYCOPROTEIN, PROTEIN-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF SYNAFFIX B.V. (NL) 2016-09-01 US disclosed
EP-3057618-A1 GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION SynAffix B.V. (NL) 2016-08-24 EP disclosed
EP-3058083-A1 MODIFIED GLYCOPROTEIN, PROTEIN-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF SynAffix B.V. (NL) 2016-08-24 EP disclosed
US-20160235861-A1 GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION SynAffix. B.V. (NL) 2016-08-18 US disclosed
EP-2935608-A1 MODIFIED GLYCOPROTEIN, PROTEIN-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF SynAffix B.V. (NL) 2015-10-28 EP disclosed
EP-2935611-A1 GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION SynAffix B.V. (NL) 2015-10-28 EP disclosed
WO-2015057066-A1 GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION SYNAFFIX B.V. (NL) 2015-04-23 WO disclosed
WO-2015057064-A1 MODIFIED GLYCOPROTEIN, PROTEIN-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF SYNAFFIX B.V. (NL) 2015-04-23 WO disclosed
WO-2015057063-A1 MODIFIED GLYCOPROTEIN, PROTEIN-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF SYNAFFIX B.V. (NL) 2015-04-23 WO disclosed
WO-2015057065-A1 GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION SYNAFFIX B.V. (NL) 2015-04-23 WO disclosed